Last reviewed · How we verify
Colchicine Tablets
Colchicine Tablets is a Alkaloid [EPC] Small molecule drug developed by Shanghai Public Health Clinical Center. It is currently FDA-approved for Cardiovascular Risk Reduction. Also known as: Colchicine, COLCRYS TM, COLCRYS, AR 374.
Colchicine tablets are a small molecule that inhibits tubulin, a protein involved in cell division. They are being studied as a potential treatment for cardiovascular diseases, particularly in patients at cardiac risk undergoing major non-cardiac surgery.
At a glance
| Generic name | Colchicine Tablets |
|---|---|
| Also known as | Colchicine, COLCRYS TM, COLCRYS, AR 374 |
| Sponsor | Shanghai Public Health Clinical Center |
| Drug class | Alkaloid [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
- Cardiovascular Risk Reduction
Common side effects
- myalgia
Drug interactions
- Strong CYP3A4 Inhibitors (atazanavir, clarithromycin, darunavir/ritonavir, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, tipranavir/ritonavir)
- Moderate CYP3A4 Inhibitors (amprenavir, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir, verapamil)
- Grapefruit/grapefruit juice
- P-glycoprotein Inhibitors (cyclosporine, ranolazine)
- HMG-CoA Reductase Inhibitors
- Other Lipid Lowering Drugs (fibrates, gemfibrozil)
- Digitalis Glycosides (digoxin)
- Oral Contraceptives (ethinyl estradiol and norethindrone)
Key clinical trials
- Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk (PHASE3)
- Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine (PHASE4)
- Proteomic and Inflammatory Omics Changes With Colchicine Therapy in Coronary Heart Disease (PHASE4)
- Mechanistic Clinical Trial of Colchicine in Patients With Peripheral Artery Disease (EARLY_PHASE1)
- Efficacy and Safety of Thalidomide for Pediatric PFAPA Syndrome (NA)
- The Peri-OPerative COlchicine to Reduce Negative Events (POPCORN) Trial (PHASE4)
- Low-dose Colchicine for Thromboprophylaxis After Transcatheter Aortic Valve Replacement (NA)
- COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Colchicine Tablets CI brief — competitive landscape report
- Colchicine Tablets updates RSS · CI watch RSS
- Shanghai Public Health Clinical Center portfolio CI
Frequently asked questions about Colchicine Tablets
What is Colchicine Tablets?
What is Colchicine Tablets used for?
Who makes Colchicine Tablets?
Is Colchicine Tablets also known as anything else?
What drug class is Colchicine Tablets in?
What development phase is Colchicine Tablets in?
What are the side effects of Colchicine Tablets?
Related
- Drug class: All Alkaloid [EPC] drugs
- Manufacturer: Shanghai Public Health Clinical Center — full pipeline
- Indication: Drugs for Cardiovascular Risk Reduction
- Also known as: Colchicine, COLCRYS TM, COLCRYS, AR 374
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing